The vaccine is delivered via commercial salmon feed by means of patented delivery systems of the US firm.
The agreement represents the first global expansion of ABN's technologies and the first international venture of the Chilean company.
The partnership between the two firms started in March 2009 when Centrovet received a registration for a freeze-dried, oral-powder vaccine to aid in the prevention of Salmon Rickettsial Syndrome (SRS) in Chilean salmonid species.
The Advanced BioNutrition's technology allows commercial fish farmers to deliver the antigen inducing an effective immune response in salmonid species. This oral vaccine will be further applied in Norway, the Faroe Islands, Scotland, the US and Canada.
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
GC Biopharma secures first Latin American approval for BARYCELA Inj.
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil